New drug combo shows promise in Hard-to-Treat sarcomas

NCT ID NCT03449901

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than standard treatment. The approach targets cancers that lack a specific protein, making them more sensitive to the therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma sarcoma small cell lung carcinoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Sarcoma Oncology Center

    Santa Monica, California, 90403, United States

  • Stanford Medicine

    Palo Alto, California, 94304, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States